Humacyte, Inc. (HUMA) Stock Forecast & Price Prediction 2024, 2025, 2030, 2040, and 2050
Discover latest Humacyte, Inc. (HUMA) short-term stock forecast for year 2024, month by month, and long-term HUMA price prediction for years 2024 to 2050. Check HUMA historical stock performance, analyst ratings (Buy, Sell, or Hold), and stay updated with the latest HUMA news and headlines.
1 Month Prediction
$10.12 [113.82%]
3 Month Prediction
$10.12 [113.77%]
6 Month Prediction
$12.37 [161.24%]
1 Year Prediction
$14.17 [199.28%]
3 Year Prediction
$23.35 [393.10%]
5 Year Prediction
$32.53 [586.92%]
About Humacyte, Inc.
Humacyte, Inc. is a biotechnology company that develops and manufactures off-the-shelf, implantable, bioengineered human tissues. Founded in 2004 by Dr. Laura Niklason, the company is located in Durham, North Carolina.
The company's primary technology platform is Human Acellular Vessels (HAV), which creates engineered blood vessels using human vascular smooth muscle cells grown on a biodegradable scaffold. These cells produce extracellular matrix proteins, which creates a vessel structure. After that, the cells are removed, which leaves a biocompatible vessel that can be implanted into patients without triggering immune rejection.
Also, the company is looking to use its HAVs for delivering cellular therapies, such as pancreatic islet cell transplantation for the treatment of Type 1 diabetes.
As of 2024, Humacyte has approximately 183 individuals
Humacyte, Inc. (HUMA) Historical Performance
IPO Date
Humacyte, Inc. (NASDAQ:HUMA) went public on 29 February, 2024.
Change
Since inception, HUMA has fallen from $10.16 to $4.74, a massive -53.4% decrease since 2021.
Historical Highs and Lows
In the past 4 years, the stock reached a high of $14.62 and a low of $2.11.
52 Week Range
$2.48
$9.97
The current price $4.74 is not near the 52-week extremes, which means that the stock is neither overbought nor underbought.
HUMA Stock Price History
Based on HUMA stock's historical price data, this table shows how the stock has performed in the last 4 years. Since 2020, the HUMA stock has fallen from $7.25 - $14.62 to $3.11 - $9.46, which is down -50.05%. Currently, the stock follows downward trend.
Here, we have calculated stock range of HUMA, indicating the highs and lows for each year, the average price based on the daily closing prices each year, and the change% from the average price.
| Year | Stock Price | Avg Price | Change% | Year Change |
|---|---|---|---|---|
| 2021 | $7.25 - $14.62 | $10.52 | 3.44 | 1 Year Change |
| 2022 | $2.11 - $7.08 | $4.44 | -56.34 | 2 Year Change |
| 2023 | $2.12 - $3.83 | $3.0 | -70.5 | 3 Year Change |
| 2024 | $3.11 - $9.46 | $5.08 | -50.05 | 4 Year Change |
HUMA Price Performance
6-Month Performance
HUMA stock dropped by 49.95% in the last six months.
1-Year Performance
The stock has trended upwards by 42.62% in the past year.
3-Year Performance
In the last 3 years, the stock has plummeted by 11.99%.
5-Year Performance
In the last 5 years, the stock has gone down by 53.44%.
According to Humacyte, Inc.'s historical data, below graph gives us the exact picture of how the HUMA stock has performed year-over-year. Here, Each bar on the graph represents a particular year that illustrates how the stock's price changed from one year to the next.
YoY Performance
In the last five years, the stock has shown positive growth in 1 year and a decline in 2 years.
2021
28.71% ↓
2022
70.90% ↓
2023
34.60% ↑
NOTE: Green bars indicate that the stock has risen compared to the previous year, while red bars show that the stock has fallen.
Humacyte, Inc. (HUMA) Financials & Stock Analysis
Market Capitalization
Humacyte, Inc. has a market capitalization of $609.27M, which places HUMA in the small-cap category.
Fundamental Analysis
EPS: $-0.33 (Q3), $-1.07 (1Y)
EPS decreased 31.25% since last quarter, and increased 791.67% since last year.
Net Income: $-39.20 M (Q3), $-110.78 M (1Y)
Net Income decreased 30.82% since last quarter, and increased 825.83% since last year.
Free Cash Flow: $-23.84 M (Q3), $-75.58 M (1Y)
Free Cash Flow increased N/A since last quarter, and increased N/A since last year.
Below, we have listed 12 key indicators for Fundamental analysis for HUMA stock. These indicators help you understand Humacyte, Inc.'s financial health, earnings and growth potential, and make a decision if the stock is a good long-term investment or not.
|
|
Technical Analysis
Here, we have listed 5 key indicators for Technical Analysis for HUMA stock. These indicators help investors study past price movements and trading volumes to forecast future price changes, and find the right time when to buy, sell or hold the stock.
| Technical Indicators | Value |
|---|---|
| SMA20 | $4.27 |
| SMA50 | $4.86 |
| SMA200 | $5.43 |
| RSI | 53.51 |
| Beta | 1.47 |
SMA20 < Current Price
This signals HUMA stock is in short-term bullish momentum.
SMA50 > Current Price
This signals HUMA stock is in mid-term bearish momentum.
SMA200 > Current Price
This signals HUMA stock is in long-term bearish momentum.
Sentiment Based on Technical Analysis
Based on 8 technical analysis indicators, the overall sentiment for HUMA stock is Neutral. Out of all indicators, 2 indicates bullish signals, 3 signals bearish trends and 4 gives neutral trends. The HUMA stock forecast was last updated on 20 December, 2024.
Humacyte, Inc. (HUMA) Stock Price Prediction and Forecast
According to short-term forecast, the stock is expected to rise to $14.17 by the end of 2025, and can reach around $8.46 to $21.99 in 2026. And, the long-term forecast suggests that the stock may further jump to $20.31 - $30.12 in 2028, and $26.11 - $66.49 by 2031. So, the HUMA stock shows a strong upward trend in the next several years.
Short-term HUMA Stock Price Prediction & Forecast
| Date | Forecasted Price | Change% |
|---|---|---|
| 2025-01 | $10.12 | 113.73% |
| 2025-02 | $11.18 | 136.11% |
| 2025-03 | $10.12 | 113.73% |
| 2025-04 | $11.09 | 134.21% |
| 2025-05 | $14.83 | 213.2% |
| 2025-06 | $12.37 | 161.25% |
| 2025-07 | $13.31 | 181.1% |
| 2025-08 | $14.16 | 199.05% |
| 2025-09 | $13.59 | 187.01% |
| 2025-10 | $13.13 | 177.3% |
| 2025-11 | $13.85 | 192.5% |
| 2025-12 | $14.17 | 199.26% |
In 2025, the HUMA stock price is expected to fluctuate between $10.12 and $14.83. According to the monthly forecast, the stock could rise to $14.17 by December 2024. If compared to the HUMA's current price, the stock could gain 199.26% by the end of this year.
Long-term HUMA Stock Price Prediction & Forecast
| Year | Year Start | Year Mid | Year End | Change% |
|---|---|---|---|---|
| 2026 | $8.46 | $33.84 | $21.99 | 364.41% |
| 2027 | $17.36 | $43.06 | $23.59 | 398.2% |
| 2028 | $20.31 | $34.58 | $30.12 | 536.11% |
| 2029 | $16.99 | $22.23 | $29.91 | 531.68% |
| 2030 | $29.72 | $43.29 | $26.35 | 456.49% |
| 2031 | $26.11 | $61.81 | $66.49 | 1304.22% |
| 2032 | $58.34 | $72.79 | $41.87 | 784.27% |
| 2033 | $51.78 | $33.22 | $89.06 | 1780.89% |
| 2034 | $52.06 | $101.00 | $43.05 | 809.19% |
| 2035 | $48.78 | $63.66 | $56.84 | 1100.42% |
| 2036 | $78.70 | $26.18 | $47.45 | 902.11% |
| 2037 | $56.83 | $65.23 | $108.21 | 2185.32% |
| 2038 | $92.27 | $65.22 | $69.76 | 1373.28% |
| 2039 | $60.14 | $40.63 | $45.43 | 859.45% |
| 2040 | $43.01 | $85.51 | $120.83 | 2451.85% |
| 2041 | $84.32 | $121.13 | $82.00 | 1631.78% |
| 2042 | $114.28 | $97.14 | $114.50 | 2318.16% |
| 2043 | $113.70 | $124.08 | $115.51 | 2339.49% |
| 2044 | $124.05 | $32.85 | $35.09 | 641.08% |
| 2045 | $73.81 | $118.99 | $205.02 | 4229.88% |
| 2046 | $128.83 | $146.57 | $194.92 | 4016.58% |
| 2047 | $143.13 | $134.60 | $95.39 | 1914.57% |
| 2048 | $133.65 | $113.68 | $129.63 | 2637.7% |
| 2049 | $174.59 | $124.72 | $113.10 | 2288.6% |
| 2050 | $147.66 | $150.00 | $80.33 | 1596.52% |
Humacyte, Inc. (HUMA) Stock Price Prediction & Forecast 2024 - 2025
At the start of 2024, the HUMA stock was at $3.32. Today, it is trading at $4.74, which is 42.62% increase from price at the beginning of the year.
In early 2025, the HUMA price is expected to climb to $16.06, a change of 239.28% from the current price. By mid-2025, the stock may move up by 38.36% on $22.22 and end the year at $20.72, which is 337.69% compared to today's price.
Humacyte, Inc. (HUMA) Stock Price Prediction & Forecast 2026 - 2030
In the next five years, there will be a significant appreciation in the HUMA stock. During this period, the HUMA's price is forecasted to shift from $8.46 to $26.35, which is 211.47% gain.
In 2026, the stock would possibly open at $8.46, escalates to $33.84 by mid-year, and wraps up at $21.99, reflecting a 364.48% increase from today's price. Further moving to 2030, the stock can kick off the year at $29.72, soar to $43.29 by mid-year, and finish at $26.35, which is 456.43% change from current price.
Humacyte, Inc. (HUMA) Stock Price Prediction & Forecast 2031 - 2040
During this period, the stock would move from $26.11 to $120.83, which is up 1304.18%
In 2031, we can expect HUMA to fluctuate between $26.11 and $66.49, a shift indicating a 1304.18% gain by year-end compared to current price. And Until 2040, HUMA can likely vary from $43.01 to $120.83. By the end of 2040, the stock could record a 2451.90% rise from today's stock price.
Humacyte, Inc. (HUMA) Stock Price Prediction & Forecast 2041 - 2050
According to long-term forecast, the HUMA stock can see an a downturn from $84.32 to $80.33 in this period. In 2041, the stock can experience a high of $121.13 by mid-year, closing the year at $82.00. This results in a 2458.25% increase from today.
Moving towards the end of 2050, HUMA is projected to open the year at $147.66. The stock may peak to $150.00 during mid-year and finish the year at $80.33. Compared to the stock's current price, this translates to an overall gain of 1596.54% by 2050.
Become a member
Get the latest news right in your inbox. We never spam!
HUMA : Buy, Sell Or Hold?
Analyst Ratings
Based on 5 analysts, 0 rated as a strong buy, 4 recommended a buy, 1 suggested a hold, 0 advised a sell, and 0 indicated a strong sell.Three months ago, out of 6 analysts, 0 analysts gave a strong buy rating, 5 a buy rating, 1 a hold rating, 0 advised selling, and 0 suggested a strong sell.So, according to analyst ratings, the recommendation for HUMA stock is Buy.
Expert Analysis
According to HUMA short-term and long-term forecast, Humacyte, Inc. shares are projected to go up by 1596.52%, and reach a value of $80.33 per share by 2050.
As per technical analysis, indicators show a Neutral sentiment, while Fear & Greed Index stands at 57.142857142857146, which signals Greed. Also, HUMA has recorded 8/30 green days, which reflects a 36.36363636363637% positivity rate with a price volatility of 0.09%.
Plus, Price-to-Earnings (P/E) ratio of 0 suggests that HUMA stock is undervalued. So, Based on HUMA prediction and analysis, it may be the best time to hold HUMA stock right now.
Disclaimer: Stock predictions, forecasts and price targets provided for "HUMA” are solely for informational and educational purposes and should not be treated as investment or financial advice. Always conduct your own research or consider consulting with a financial advisor before making any investment decisions.